Filtered By:
Education: Academia
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 233 results found since Jan 2013.

Protected Percutaneous Coronary Intervention of Unprotected Left Main Using Impella Ventricular Assist Device Before Transcatheter Aortic Valve Implantation: A Single-Center Experience
CONCLUSION: Temporary hemodynamic support with the Impella device during staged approach with high-risk protected PCI appears to be safe and technically feasible in patients with severe AS before undergoing TAVI.PMID:35058376
Source: The Journal of Invasive Cardiology - January 21, 2022 Category: Cardiology Authors: Kinan Kneizeh Anas Alnaimi Timothee Noterdaeme J örg Schröder Ertunc Altiok Nikolaus Marx Mohammad Almalla Source Type: research

Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
CONCLUSION: In Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.PMID:34904209 | DOI:10.1007/s12325-021-01907-3
Source: Adv Data - December 14, 2021 Category: Epidemiology Authors: Dandan Li Yang Sun Xiaoran Ye Lanting Li Yundai Chen Daowen Wang Source Type: research

White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial
Conclusion There was no association between baseline WBCc and 30-day or 5-year clinical outcomes after PCI or CABG. The absence of a clear incremental increase in events with increasing WBCc in the current analysis indicates that WBCc should not routinely be used as a prognostic marker or to guide revascularization decisions in patients with LMCAD.
Source: Coronary Artery Disease - December 9, 2021 Category: Cardiology Tags: PCI Source Type: research

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
CONCLUSIONS: The bleeding risk of ticagrelor was attenuated in Korean patients with AMI without HBR. Appropriate patient selection could reduce in-hospital bleeding complications associated with ticagrelor in Korean patients with AMI who underwent successful PCI.PMID:34725976 | DOI:10.3346/jkms.2021.36.e268
Source: J Korean Med Sci - November 2, 2021 Category: General Medicine Authors: Keun-Ho Park Myung Ho Jeong Hyun Kuk Kim Young-Jae Ki Sung Soo Kim Dong-Hyun Choi Young-Youp Koh Youngkeun Ahn Hyo-Soo Kim Hyeon-Cheol Gwon Seung-Woon Rha Jin-Yong Hwang KAMIR-NIH registry investigators Source Type: research